Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-17

Study Completion Date

2022-07-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ZX-101A-101 is a Phase 1/2a, first-in-human, open-label, multicenter, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary antitumor activity of ZX-101A administered orally (PO) once daily (QD) in 28-day cycles in patients with relapsed/resistant or refractory advanced hematologic malignancies \[Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), indolent NHL, and other NHL subtypes).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

NCT05269940

Non Hodgkin Lymphoma Peripheral T Cell Lymphoma CLL/SLL

COMPLETED PHASE1/PHASE2

To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

NCT05740917

AML MDS

UNKNOWN PHASE1

Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML

NCT02238522

Lymphoproliferative Malignancies Acute Myeloid Leukemia

WITHDRAWN PHASE1

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

NCT04951778

Leukemia, Myeloid, Acute Myelodysplastic Syndromes

TERMINATED PHASE1

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06618001

Leukemia, Myeloid, Acute Myelodysplastic Neoplasms

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ZX-101A-101 study will consist of 2 parts:

* Part 1: ZX-101A Dose Escalation
* Part 2: ZX-101A Dose Expansion

The Part 1 (dose escalation) of the study is designed to determine the safety and tolerability of ZX-101A administered orally once daily in 28-day cycles. The Part 2 (dose expansion) of the study is designed to further investigate the safety, tolerability, pharmacokinetics and pharmacodynamic and clinical activities of ZX-101A administered orally once daily in 28-day cycles at the selected recommended Phase 2 dose (RP2D).

Results of clinical findings in patients in the dose-escalation portion of the study will be reviewed to identify conditions (or genetic characteristics) most likely to respond to ZX-101A. These select types of hematologic malignancies will be enrolled in cohorts in the dose-expansion part of the study.

Male or female patients who are 18 years of age or older with relapsed/resistant or refractory advanced hematologic malignancies (CLL/SLL, iNHL, and other NHL subtypes) will be included in the study provided that all inclusion and exclusion criteria are satisfied.

Up to three cohorts are planned in Part 2 - Dose Expansion of the study: 1) relapsed/resistant or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), 2) relapsed/resistant or refractory indolent Non- Hodgkin's Lymphoma (iNHL), and based on emerging data from Part 1-Dose Expansion, a third cohort consisting of other types of NHL may be included.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-hodgkin Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ZX-101A

Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females who are ≥ 18 years old
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
* Failed at least 2 prior systemic standard therapies.
* Histopathological confirmed diagnosis of CLL/SLL, indolent NHL,and other NHL subtypes.
* Documented active disease that is relapsed/resistant or refractory requiring treatment after established therapy shown to have clinical benefit.
* Acceptable bone marrow, kidney, and liver function.
* No transfusion or cytokine support for ≥ 2 weeks before initiating study treatment.

Exclusion Criteria

* Negative serum pregnancy test in women of childbearing potential at Screening.
* Women of childbearing potential and men who partner with a woman of childbearing potential must agree to use effective contraceptive methods.
* Men must agree to no sperm donations during the study and for 3 months after the last dose of ZX-101A.
* Understands the requirements of the study (e.g. periodic imaging studies, periodic blood sampling, bone marrow studies), is willing to comply with all study procedures and signed the Institutional Review Board (IRB)-approved informed consent.

* Received investigational study drug within 28 days (or 5 half-lives, whichever is longer).
* Concurrent participation in another therapeutic treatment trial.
* Received approved anti-cancer drugs within 21 days (42 days for nitrosoureas) or 5 half-lives, whichever is longer.
* Ongoing immunosuppression for chronic conditions.
* Known active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV infection.
* Any concurrent uncontrolled illness.
* Has not recovered from adverse events from prior anti-cancer treatment (with exception of alopecia).
* Pregnant or breast-feeding or planning to conceive or father children within the projected duration of the study.
* Major surgery within 4 weeks prior to first dose of study treatment.
* Radiation treatment within 2 weeks prior to first dose of study treatment.
* Gastrointestinal dysfunction, including motility or malabsorption syndromes or inflammatory bowel disease which could limit absorption of study drug.
* Active or prior pneumonitis or interstitial lung disease.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No